Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of mitapivat in transfusion-dependent alpha- and beta-thalassemia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-thalassemia
• Beta-thalassemia

Drugs mentioned

• Mitapivat (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-25